Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Importance: Biological therapies have revolutionized inflammatory bowel disease management, but many patients do not respond to biological monotherapy. Identification of likely responders could reduce costs and delays in remission. Objective: To identify patients with Crohn disease likely to be durable responders to ustekinumab before committing to long-term treatment. Design, Setting, and Participants: This cohort study analyzed data from 3 phase 3 randomized clinical trials (UNITI-1, UNITI-2, and IM-UNITI) conducted from 2011 to 2015. Participants (n = 401) were individuals with active (C-reactive protein [CRP] measurement of ≥5 mg/L at enrollment) Crohn disease who received ustekinumab therapy. Data analysis was performed from November 1, 2017, to June 1, 2018. Exposures: All included patients were exposed to 1 or more dose of ustekinumab for 8 weeks or more. Main Outcomes and Measures: Random forest methods were used in building 2 models for predicting Crohn disease remission, with a CRP level lower than 5 mg/dL as a proxy for biological remission, beyond week 42 of ustekinumab treatment. The first model used only baseline data, and the second used data through week 8. Results: In total, 401 participants, with a mean (SD) age of 36.3 (12.6) years and 170 male (42.4%), were included. The week-8 model had a mean area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI, 0.69-0.87). In the testing data set, 27 of 55 participants (49.1%) classified as likely to have treatment success achieved success with a CRP level lower than 5 mg/L after week 42, and 7 of 65 participants (10.8%) classified as likely to have treatment failure achieved this outcome. In the full cohort, 87 patients (21.7%) attained remission after week 42. A prediction model using the week-6 albumin to CRP ratio had an AUROC of 0.76 (95% CI, 0.71-0.82). Baseline ustekinumab serum levels did not improve the model's prediction performance. Conclusions and Relevance: In patients with active Crohn disease, demographic and laboratory data before week 8 of treatment appeared to allow the prompt identification of likely nonresponders to ustekinumab without the need for costly drug-level monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Shivashankar, R., Tremaine, W. J., Harmsen, W. S., & Loftus, E. V. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.039 · Cited by 455
Cited by
The four epidemiological stages in the global evolution of inflammatory bowel disease
Kaplan, G. G., & Windsor, J. W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00360-x · Cited by 1,351
Gubatan, J., Levitte, S., Patel, A., Balabanis, T., Wei, M. T., & Sinha, S. R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1920 · Cited by 121
Ahmad, H. A., East, J. E., Panaccione, R., Travis, S., Canavan, J. B., Usiskin, K., & Byrne, M. F. (2023) · Intestinal Research · doi:10.5217/ir.2023.00020 · Cited by 37
Machine learning predictive outcomes modeling in inflammatory bowel diseases
Javaid, A., Shahab, O., Adorno, W., Fernandes, P., May, E., & Syed, S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab187 · Cited by 36
Metadata
- Authors
- Waljee, A. K., Wallace, B. I., Cohen-Mekelburg, S., Liu, Y., Liu, B., Sauder, K., Stidham, R. W., Zhu, J., & Higgins, P. D. R.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2019-05-10
- Volume
- 2
- Issue
- 5
- Pages
- e193721
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2944098284
- Cited by
- 98
- References
- 2
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2019.3721
- The paper
- Waljee, A. K., Wallace, B. I., Cohen-Mekelburg, S., Liu, Y., Liu, B., Sauder, K., Stidham, R. W., Zhu, J., & Higgins, P. D. R. (2019). Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2019.3721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.